Eli Lilly and Company (LLY)
NYSE Market Closed
Eli Lilly & Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and commercialising prescription medicines. The company has a long history in diabetes care and has expanded into several high-value therapeutic areas, including obesity, oncology, immunology, neuroscience, and cardiometabolic disease. Lilly sells medicines through healthcare systems, pharmacies, hospitals, and specialist channels in the United States and international markets.
A central part of Lilly’s current profile is its cardiometabolic portfolio. Mounjaro, used for type 2 diabetes, and Zepbound, used for chronic weight management, are based on tirzepatide and have become major growth drivers as demand for GLP-1 and related incretin therapies increases. Lilly also markets established diabetes products such as Trulicity, Jardiance, Humalog, and Humulin, giving it broad exposure across modern and legacy diabetes treatment.
Beyond metabolic disease, Lilly has important positions in cancer and immunology. Verzenio is used in certain breast cancer settings, while Jaypirca targets specific blood cancers. Taltz and Olumiant are part of the company’s immunology franchise, addressing inflammatory and autoimmune conditions. In neuroscience, Lilly is active in areas such as Alzheimer’s disease and migraine, supported by a research pipeline that aims to produce differentiated therapies for complex neurological disorders.
The company’s investment case is closely tied to product innovation, clinical trial execution, regulatory approvals, manufacturing capacity, and pricing dynamics. Lilly competes with other large drugmakers but stands out for the scale of its obesity and diabetes opportunity, its strong research base, and its ability to turn specialised medicines into global commercial franchises.
Last updated
- Market Cap
- $1,059,906,000,343
- P/E
- 41.93
- P/FCF
- 89.65
- P/S
- 14.67
- Enterprise Value
- $1,097,994,000,343
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group
Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors
1 Vanguard Index Fund to Buy Before It Soars in 2026, According to a Wall Street Analyst
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?
Which is the Better Choice for Healthcare Investors? IYH or BBH?
Which is the Better Choice for Healthcare Investors? IYH or BBH?
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
Should You Buy Eli Lilly Stock? Here's My Honest Take.
History Says Doing This 1 Thing Will Score You an Investing Win -- Even After a Market Crash.
Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
The Roth Advantage Most VUG Investors Overlook
Eli Lilly Stock Gets a Lift After Canada Backs Eczema Drug
1 Unpopular Stock That Should Get More Attention and 2 That Underwhelm
Innovent’s China Verzenios Deal and New Jaypirca Nod Might Change The Case For Investing In Eli Lilly (LLY)
My Forever Portfolio: 5 Undervalued Stocks to Buy Now and Hold Forever
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $1,059,906,000,343
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $1,097,994,000,343
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 41.93
- P/B
P/B ratio compares a company's share price to its book value per share.
- 33.97
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 14.67
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 30.32
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 15.2
- EPS
- 28.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.53%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 89.65
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 51.75
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $11,822,900,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 81.02%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 21.68%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.39
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.5
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.1
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.14
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $3,293,089
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1,188.58
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 19.8B | 19.29B | 17.6B | 15.56B | 12.73B |
| Cost of revenue | 3.58B | 3.37B | 3.01B | 2.45B | 2.23B |
| Gross profit | 16.22B | 15.92B | 14.59B | 13.11B | 10.5B |
| Operating income | 8.92B | 8.37B | 7.37B | 6.87B | 3.7B |
| EBITDA | 10.29B | 9.57B | 8.86B | 7.5B | 5.77B |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Income taxes | 1.45B | 1.63B | 1.65B | 1.12B | 697M |
| Other operating expenses | 863M | 612.9M | 1.02B | 153.8M | 1.61B |
| Total operating expenses | 7.31B | 7.55B | 7.23B | 6.24B | 6.81B |
| Basic EPS | 8.27 | 7.4 | 6.22 | 6.3 | 3.07 |
| Diluted EPS | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 116.58B | 112.48B | 114.94B | 100.92B | 89.39B |
| Total liabilities | 85.38B | 85.94B | 91.08B | 82.57B | 73.54B |
| Total equity | 31.2B | 26.54B | 23.85B | 18.35B | 15.85B |
| Cash & equivalents | 5.28B | 7.27B | 9.79B | 3.38B | 3.09B |
| Current assets | 54.84B | 55.63B | 62.07B | 49.85B | 41.26B |
| Current liabilities | 36.63B | 35.23B | 40.14B | 39.02B | 30.07B |
| Accounts payable | 5.03B | 5.38B | 4.26B | 4.08B | 3.44B |
| Receivables | 21.18B | 20.16B | 19.46B | 17.21B | 14B |
| Inventories | 14.53B | 13.74B | 12.18B | 11.01B | 9.31B |
| Goodwill | 6.13B | 5.9B | 5.9B | 5.77B | 5.77B |
| Long-term debt | 39.37B | 40.87B | 40.87B | 34.18B | 34.5B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B |
| Investing cash flow | -3.92B | -2.8B | -2.98B | -1.83B | -3.35B |
| Financing cash flow | -3.47B | -2.88B | 531M | -1.24B | 1.38B |
| Change in cash | -1.99B | -2.52B | 6.42B | 282.6M | -175M |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 11-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Yuffa Ilya | View Filing | |
| edgar index | 25-NSE — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | SD — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | FWP — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| edgar index | SCHEDULE 13G — ELI LILLY & Co | View Filing | |
| edgar index | PX14A6G — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| edgar index | DEF 14A — ELI LILLY & Co | View Filing | |
| edgar index | DEFA14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | PRE 14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free